Use of the Omnipod 5 led to an HbA1c reduction of 0.8 percentage points at 13 weeks for adults with type 2 diabetes. FDA cleared the device for use in adults with type 2 diabetes in August.

Biomerica, Inc. has achieved IVDR certification for its food intolerance products designed for managing Crohn's Disease and Ulcerative Colitis, marking a significant step in compliance with ...